Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406056 | 1.00 | CA1 (0.46) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL2430897 | 1.00 | CA1 (0.46) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL1563474 | 0.95 | HTT (0.43) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL1439006 | 0.89 | LMNA (0.42) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL866209 | 0.89 | LMNA (0.42) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL376155 | 0.89 | LMNA (0.42) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL15491932 | 0.86 | CA1 (0.46) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL26489819 | 0.83 | HPGD (0.47) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL26489822 | 0.82 | GFER (0.49) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL26489825 | 0.82 | GFER (0.52) | CA1CA2CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2025-05-01 | — | — | US | disclosed |
| CN-113105475-B | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-113105475-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2021-07-13 | — | — | CN | disclosed |
| US-10227333-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160058768-A1 | SUBSTITUTED AMIDE COMPOUNDS | PFIZER (US) | 2016-03-03 | — | — | US | disclosed |
| US-8940725-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8461158-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2134346-B1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2360158-A1 | Pyrazole derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-08-24 | — | — | EP | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
| US-7795256-B2 | Thieno-pyridinone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2010-09-14 | — | — | US | disclosed |
| US-20070078131-A1 | Thieno-pyridinone derivatives as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, ERBB4 | CA1 695/4885CA2 1351/4885CA12 970/4885 |
| US-20160058768-A1 | SUBSTITUTED AMIDE COMPOUNDS | CETP, APOB, LCAT | CA1 4730/4885CA2 4827/4885CA12 4797/4885 |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | CA1 4643/4885CA2 3522/4885CA12 4022/4885 |
| US-10227333-B2 | Inhibition of OLIG2 activity | GLI2, ING2, GMFG | CA1 1114/4885CA2 2144/4885CA12 2110/4885 |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | CA1 1036/4885CA2 93/4885CA12 1432/4885 |
| US-20070078131-A1 | Thieno-pyridinone derivatives as kinase inhibitors | MAP3K6, MAP4K2, MAP3K15 | CA1 4881/4885CA2 4838/4885CA12 4884/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | CA1 3786/4885CA2 1470/4885CA12 3727/4885 |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | CA1 1114/4885CA2 2144/4885CA12 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.